Dermatitis, Atopic

Dermatology
22
Pipeline Programs
12
Companies
26
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
2
0
9
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
5100%
+ 25 programs with unclassified modality

On Market (1)

Approved therapies currently available

Regeneron
DUPIXENTApproved
dupilumab
Regeneron
Interleukin-4 Receptor alpha Antagonist [EPC]injection2017

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
10 programs
4
6
Locobase® REPAIRPhase 41 trial
ProtopicPhase 41 trial
Tacrolimus 0.03%Phase 41 trial
tacrolimus 0.1%Phase 41 trial
tacrolimus ointmentPhase 41 trial
+5 more programs
Active Trials
NCT00523952Completed303Est. Sep 2005
NCT00480610Completed226Est. Nov 2005
NCT00480896Completed250Est. Nov 2005
+7 more trials
Regeneron
RegeneronTARRYTOWN, NY
3 programs
3
1
DupilumabPhase 3Monoclonal Antibody
DupilumabPhase 3Monoclonal Antibody
DupilumabPhase 3Monoclonal Antibody
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
4 programs
2
2
WAL 801 CL Dry SyrupPhase 31 trial
WAL 801 CL dry syrupPhase 31 trial
BI 655130Phase 21 trial
SpesolimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03822832Completed51Est. Jul 2020
NCT04086121Terminated14Est. Feb 2022
NCT02182557Completed162
+1 more trials
GSK
GSKLONDON, United Kingdom
1 program
1
Combination therapy GSK2894512 Cream A + GSK2894512 Cream BPhase 11 trial
Active Trials
NCT02411162Completed15Est. Sep 2015
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
1
IMVAMUNEPhase 11 trial
Active Trials
NCT00189917Completed60
Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
1 program
1
LY3471851Phase 1
Pfizer
PfizerNEW YORK, NY
1 program
1
P3-FastPhase 11 trial
Active Trials
NCT04065633Completed46Est. Dec 2019
Bayer
BayerLEVERKUSEN, Germany
5 programs
BAY987534N/A1 trial
Diflucortolone valerateN/A1 trial
MINERAL OIL + PETROLATUMN/A1 trial
PhoenixN/A1 trial
Phoenix IIN/A1 trial
Active Trials
NCT03672383Completed42Est. Oct 2018
NCT02627989Completed55Est. Jan 2017
NCT06747897Completed300Est. Dec 2024
+2 more trials
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
2 programs
Gel CreamN/A1 trial
Wash IPN/A1 trial
Active Trials
NCT05226143Completed37Est. Mar 2022
NCT04740892Completed31Est. Feb 2023
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
Clinical and instrumental measurementsN/A1 trial
Active Trials
NCT05639738Terminated12Est. Jun 2022
Sanofi
SanofiPARIS, France
1 program
DupilumabN/AMonoclonal Antibody1 trial
Active Trials
NCT03428646Active Not Recruiting858Est. Mar 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AstellasLocobase® REPAIR
AstellasProtopic
AstellasTacrolimus 0.03%
Astellastacrolimus 0.1%
Astellastacrolimus ointment
Astellastacrolimus ointment
Astellastacrolimus ointment
Astellastacrolimus ointment
Astellastacrolimus ointment
Astellastacrolimus ointment
Boehringer IngelheimWAL 801 CL Dry Syrup
Boehringer IngelheimWAL 801 CL dry syrup
Boehringer IngelheimSpesolimab
Boehringer IngelheimBI 655130
PfizerP3-Fast

Showing 15 of 26 trials with date data

Clinical Trials (26)

Total enrollment: 5,087 patients across 26 trials

NCT00673725AstellasLocobase® REPAIR

Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis

Start: Mar 2008Est. completion: Sep 200849 patients
Phase 4Completed

A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis

Start: Oct 2004Est. completion: Jul 2006410 patients
Phase 4Completed
NCT00689832AstellasTacrolimus 0.03%

Protopic Ointment in Children Atopic Eczema

Start: Feb 2004Est. completion: Aug 2005487 patients
Phase 4Completed
NCT00690105Astellastacrolimus 0.1%

Protopic Ointment in Adult Atopic Eczema of the Face

Start: Feb 2004Est. completion: Jul 2005577 patients
Phase 4Completed
NCT00667160Astellastacrolimus ointment

Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis

Start: Dec 2002Est. completion: Nov 2003426 patients
Phase 4Completed
NCT00666302Astellastacrolimus ointment

A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis

Start: Oct 2002Est. completion: Nov 2003413 patients
Phase 4Completed
NCT00480896Astellastacrolimus ointment

Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment

Start: Jun 2004Est. completion: Nov 2005250 patients
Phase 3Completed
NCT00480610Astellastacrolimus ointment

Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment

Start: Apr 2004Est. completion: Nov 2005226 patients
Phase 3Completed
NCT00523952Astellastacrolimus ointment

Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients

Start: Jan 2004Est. completion: Sep 2005303 patients
Phase 3Completed
NCT00691262Astellastacrolimus ointment

Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis

Start: Oct 2003Est. completion: Feb 2005166 patients
Phase 3Completed

WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients

Start: Jun 2001162 patients
Phase 3Completed

WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients

Start: Jun 200162 patients
Phase 3Completed

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

Start: Sep 2019Est. completion: Feb 202214 patients
Phase 2Terminated

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Start: Feb 2019Est. completion: Jul 202051 patients
Phase 2Completed

Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation

Start: Jul 2019Est. completion: Dec 201946 patients
Phase 1Completed
NCT02411162GSKCombination therapy GSK2894512 Cream A + GSK2894512 Cream B

A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

Start: Jul 2015Est. completion: Sep 201515 patients
Phase 1Completed

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

Start: Apr 200460 patients
Phase 1Completed
NCT06747897BayerMINERAL OIL + PETROLATUM

An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Children With Eczema or Dry Skin

Start: Nov 2024Est. completion: Dec 2024300 patients
N/ACompleted
NCT05639738Pierre FabreClinical and instrumental measurements

Assessment of Clinical, Biological and Biometrological Paramaters in Adult Subjects Suffering From AD

Start: Mar 2022Est. completion: Jun 202212 patients
N/ATerminated

A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area

Start: Feb 2022Est. completion: Mar 202237 patients
N/ACompleted

A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children

Start: Jan 2021Est. completion: Feb 202331 patients
N/ACompleted

Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)

Start: Sep 2018Est. completion: Oct 201842 patients
N/ACompleted

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

Start: Apr 2018Est. completion: Mar 2027858 patients
N/AActive Not Recruiting
NCT02627989BayerDiflucortolone valerate

An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids

Start: Dec 2015Est. completion: Jan 201755 patients
N/ACompleted

Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis

Start: Oct 2013Est. completion: Jun 201435 patients
N/ACompleted

Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis

Start: Oct 2013Est. completion: Jun 20140
N/AWithdrawn

Related Jobs in Dermatology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

9 late-stage (Phase 3) programs — potential near-term approvals
12 companies competing in this space